AG2R LA Mondiale Gestion D Actifs Buys Shares of 18,239 DexCom, Inc. $DXCM

Key Points

• AG2R LA Mondiale Gestion D Actifs has made a new investment of approximately $1.25 million in DexCom, Inc., acquiring 18,239 shares of the medical device company's stock during the 1st quarter.
• DexCom reported earnings of $0.48 per share for the last quarter, exceeding expectations, alongside a revenue of $1.16 billion, which reflects a 15.2% increase compared to the same quarter last year.
• Analysts have generally bullish sentiments toward DexCom, increasing price targets; with Morgan Stanley and Barclays raising theirs to $89.00 and $98.00, respectively, while maintaining "equal weight" ratings.

AG2R LA Mondiale Gestion D Actifs bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 18,239 shares of the medical device company's stock, valued at approximately $1,246,000.

A number of other hedge funds have also added to or reduced their stakes in DXCM. Golden State Wealth Management LLC increased its stake in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of DexCom in the 1st quarter worth $27,000. Heck Capital Advisors LLC purchased a new stake in shares of DexCom in the 4th quarter worth $38,000. Anderson Financial Strategies LLC purchased a new stake in shares of DexCom in the 1st quarter worth $37,000. Finally, Alpine Bank Wealth Management purchased a new stake in shares of DexCom in the 1st quarter worth $40,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Morgan Stanley upped their price objective on DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. William Blair upgraded DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Mizuho upped their target price on shares of DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Argus initiated coverage on shares of DexCom in a report on Thursday, August 21st. They issued a "buy" rating and a $100.00 target price for the company. Finally, UBS Group upped their target price on shares of DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $99.89.

DexCom Price Performance

Shares of DXCM traded up $0.97 during midday trading on Tuesday, hitting $76.55. 4,300,479 shares of the company traded hands, compared to its average volume of 4,073,249. The firm has a 50 day moving average of $80.58 and a 200-day moving average of $78.47. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The stock has a market cap of $30.02 billion, a price-to-earnings ratio of 53.16, a PEG ratio of 1.58 and a beta of 1.48. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the firm earned $0.43 EPS. The business's revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the transaction, the director directly owned 51,121 shares of the company's stock, valued at approximately $4,143,868.26. This trade represents a 5.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Sadie Stern sold 1,466 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $88.99, for a total transaction of $130,459.34. Following the transaction, the executive vice president directly owned 106,689 shares in the company, valued at approximately $9,494,254.11. This trade represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,315 shares of company stock worth $689,431 in the last 90 days. 0.32% of the stock is currently owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.